Literature DB >> 8922741

5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats.

M R MacLean1, G Sweeney, M Baird, K M McCulloch, M Houslay, I Morecroft.   

Abstract

1. We investigated 5-hydroxytryptamine (5-HT)-receptor mediated vasoconstriction in the main, first branch and resistance pulmonary arteries removed from control and pulmonary hypertensive rats. Contractile responses to 5-HT, 5-carboxamidotryptamine (5-CT, non-selective 5-HT1 agonist), and sumatriptan (5-HT1D-like receptor agonist) were studied. The effects of methiothepin (non-selective 5-HT1 + 2-receptor antagonist) and ketanserin (5-HT2A receptor antagonist) and GR55562 (a novel selective 5-HT1D receptor antagonist) on 5-HT-mediated responses were also studied. Basal levels of adenosine 3':5'-cyclic monophosphate ([cyclic AMP]i) and guanosine 3':5'-cyclic monophosphate ([cyclic GMP]i) were determined and we assessed the degree of inherent tone in the vessels under study. 2. 5-HT was most potent in the resistance arteries. pEC50 values were 5.6 +/- 0.1, 5.3 +/- 0.1, 5.0 +/- 0.2 in the resistance arteries, pulmonary branch and main pulmonary artery, respectively (n = at least 5 from 5 animals). The sensitivity to, and maximum response of, 5-HT was increased in all the arteries removed from the chronic hypoxic (CH) rats. In CH rats the pEC50 values were 5.9 +/- 0.2, 6.3 +/- 0.2, 6.4 +/- 0.2 and the increase in the maximum response was 35%, 51% and 41% in the resistance arteries, pulmonary branch and main pulmonary artery, respectively. Sumatriptan did not contract any vessel from the control rats whilst 5-CT did contract the resistance arteries. In the CH rats, however, they both contracted the resistance arteries (responses to sumatriptan were small) (pEC50: 5-CT; 5.4 +/- 0.2) and the pulmonary artery branches (pEC50: sumatriptan, 5.4 +/- 0.2; 5-CT, 5.4 +/- 0.2). 5-CT also caused a contraction in the main pulmonary artery (pEC50: 6.0 +/- 0.3). 3. Ketanserin (1 nM-1 microM) caused a competitive antagonism of the 5-HT response in all vessels tested. In control rats, the estimated pKb values for ketanserin in resistance arteries, pulmonary branches and main pulmonary artery were 8.3, 7.8 and 9.2, respectively. Methiothepin (1 nM-1 microM) inhibited responses to 5-HT in the first branch (estimated pKb value: 7.8) and main pulmonary artery. In CH rats, the estimated pKb values for ketanserin in resistance arteries, pulmonary branches and main pulmonary artery were 7.7, 8.3 and 9.6, respectively. Methiothepin also inhibited contractions to 5-HT in the pulmonary artery branch and main pulmonary artery with estimated pKb values of 7 and 9.5, respectively. In control animals, GR55562 had no effect on responses to 5-HT in any of the vessels tested. In the CH rats the estimated pKb values for GR55562 were 6.5, 7.8 and 7.0 in the pulmonary resistance arteries, first branch and main pulmonary artery, respectively. 4. Large pulmonary arteries from controls demonstrated inherent tone and this was increased three fold in the CH rats. The resistance arteries from controls demonstrated little inherent tone though this was enhanced in those from the CH rats. 5. [Cyclic AMP]i was 259 +/- 23 pmol mg-1 protein in the pulmonary artery branches removed from control rats and decreased to 192 +/- 11 pml mg-1 protein in the CH rats (P < 0.01, n = 8). [Cyclic GMP]i also decreased in the pulmonary artery branches (from 550 +/- 15, control to 462 +/- 31 pmol mg-1 protein in CH vessels, n = 8, P < 0.01) and in the main pulmonary arteries (from 566 +/- 33, control to 370 +/- 25 pmol mg-1 protein in CH vessels, n = 8, P < 0.001). No changes in either [cyclic AMP]i or [cyclic GMP]i were observed in the resistance arteries. 6. The results suggest that the increased vasoconstrictor response to 5-HT in CH rat pulmonary arteries is due to an increase in 5-HT2A-receptor mediated contraction combined with an increase in r5-HT1B-like receptor-mediated contraction. An increase in vascular tone and decreased levels of [cyclic GMP]i in the large pulmonary arteries may contribute to the observed increase in activity of r5-HT1B-like receptor

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8922741      PMCID: PMC1915945          DOI: 10.1111/j.1476-5381.1996.tb15760.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  5-HT1-receptor-mediated vasoconstriction in bovine isolated pulmonary arteries: influences of vascular endothelium and tone.

Authors:  M R MacLean; R A Clayton; S W Hillis; P D McIntyre; A J Peacock; A G Templeton
Journal:  Pulm Pharmacol       Date:  1994-02

2.  Multiple phenotypically distinct smooth muscle cell populations exist in the adult and developing bovine pulmonary arterial media in vivo.

Authors:  M G Frid; E P Moiseeva; K R Stenmark
Journal:  Circ Res       Date:  1994-10       Impact factor: 17.367

3.  Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain.

Authors:  A T Bruinvels; J M Palacios; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

4.  5-HT1B receptors mediate potent contractile responses to 5-HT in rat caudal artery.

Authors:  D A Craig; G R Martin
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

5.  Acute and prolonged hypoxia attenuate endothelial nitric oxide production in rat pulmonary arteries by different mechanisms.

Authors:  P W Shaul; L B Wells; K M Horning
Journal:  J Cardiovasc Pharmacol       Date:  1993-12       Impact factor: 3.105

Review 6.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

7.  Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats.

Authors:  Y Kanai; S Hori; T Tanaka; M Yasuoka; K Watanabe; N Aikawa; Y Hosoda
Journal:  Cardiovasc Res       Date:  1993-09       Impact factor: 10.787

8.  Increased endothelium-derived NO in hypertensive pulmonary circulation of chronically hypoxic rats.

Authors:  T C Isaacson; V Hampl; E K Weir; D P Nelson; S L Archer
Journal:  J Appl Physiol (1985)       Date:  1994-02

9.  Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles.

Authors:  M R MacLean; K M McCulloch; M Baird
Journal:  J Cardiovasc Pharmacol       Date:  1994-05       Impact factor: 3.105

10.  Distribution of NOS in normoxic vs. hypoxic rat lung: upregulation of NOS by chronic hypoxia.

Authors:  C Xue; A Rengasamy; T D Le Cras; P A Koberna; G C Dailey; R A Johns
Journal:  Am J Physiol       Date:  1994-12
View more
  39 in total

Review 1.  5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.

Authors:  M R MacLean; P Herve; S Eddahibi; S Adnot
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

2.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

3.  Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.

Authors:  Fiona Murray; Margaret R MacLean; Nigel J Pyne
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

4.  Reduction of reactive oxygen species prevents hypoxia-induced CREB depletion in pulmonary artery smooth muscle cells.

Authors:  Dwight J Klemm; Susan M Majka; Joseph T Crossno; John C Psilas; Jane E B Reusch; Chrystelle V Garat
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

5.  5-HT moduline: an endogenous inhibitor of 5-HT(1B/1D)-mediated contraction in pulmonary arteries.

Authors:  R Murdoch; I Morecroft; M R MacLean
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 6.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

7.  Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARγ axis.

Authors:  Jian Wang; Kai Yang; Lei Xu; Yi Zhang; Ning Lai; Hua Jiang; Yajie Zhang; Nanshan Zhong; Pixin Ran; Wenju Lu
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

8.  Effect of chronic perinatal hypoxia on the role of rho-kinase in pulmonary artery contraction in newborn lambs.

Authors:  Arlin B Blood; Michael H Terry; Travis A Merritt; Demosthenes G Papamatheakis; Quintin Blood; Jonathon M Ross; Gordon G Power; Lawrence D Longo; Sean M Wilson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

9.  Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts.

Authors:  K M Mair; M R MacLean; I Morecroft; Y Dempsie; T M Palmer
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

10.  The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice.

Authors:  Lakshmi Kugathasan; Julie Basu Ray; Yupu Deng; Effat Rezaei; Daniel J Dumont; Duncan J Stewart
Journal:  J Exp Med       Date:  2009-09-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.